Central nervous system relapse of acute promyelocytic leukemia

2009 ◽  
pp. n/a-n/a ◽  
Author(s):  
Donna L. Johnston ◽  
Karen Mandel
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Acute Promyelocytic Leukemia ◽  
Promyelocytic Leukemia ◽  
Central Nervous System Relapse

Central nervous system relapse in acute promyelocytic leukemia

2002 ◽  
Vol 71 (1) ◽  
pp. 60-61 ◽  
Author(s):  
N. Colovic ◽  
A. Bogdanovic ◽  
P. Miljic ◽  
G. Jankovic ◽  
M. Colovic
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Acute Promyelocytic Leukemia ◽  
Promyelocytic Leukemia ◽  
Central Nervous System Relapse

scholarly journals Treatment of Central Nervous System Relapse in Acute Promyelocytic Leukemia by Venetoclax: A Case Report

2021 ◽  
Vol 11 ◽  
Author(s):  
Xuzhao Zhang ◽  
Jinliang Chen ◽  
Weiqin Wang ◽  
Xian Li ◽  
Yanbin Tan ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Acute Promyelocytic Leukemia ◽  
Oral Treatment ◽  
Central Nervous System Involvement ◽  
Promyelocytic Leukemia ◽  
Lymphocytic Leukemia ◽  
Central Nervous System Relapse ◽  
Extramedullary Relapse ◽  
New Treatment

Extramedullary relapse of acute promyelocytic leukemia is a rare phenomenon and is associated with a poor prognosis, with the central nervous system being the most common site of relapse. The current treatments are still limited. Venetoclax, a selective inhibitor of BCL2, is a small molecule that can cross the blood-brain barrier and shows a potential efficacy in the treatment of chronic lymphocytic leukemia with central nervous system involvement. Although venetoclax has also been used in the treatment of acute myeloid leukemia in recent years, there are no reports of its use in the treatment of central nervous system relapse in acute promyelocytic leukemia. Here, we report a case of central nervous system relapse in acute promyelocytic leukemia that achieved complete remission after oral treatment with venetoclax. The presence of venetoclax in the patient’s CSF was confirmed by testing CSF and plasma by mass spectrometry. The concentration of venetoclax in CSF was approximately 1/300 of that in plasma trough concentration. The treatment experience in this case demonstrates the potential ability of venetoclax to treat of central nervous system relapse/involvement in acute promyelocytic leukemia, thus providing a new treatment option for this kind of patient.

Isolated Central Nervous System Relapse in Childhood Acute Promyelocytic Leukemia

2008 ◽  
Vol 30 (2) ◽  
pp. 160-162 ◽  
Author(s):  
Katrin Scheinemann ◽  
Sheila Weitzman ◽  
Johann Hitzler ◽  
John Doyle ◽  
Oussama Abla
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Acute Promyelocytic Leukemia ◽  
Promyelocytic Leukemia ◽  
Central Nervous System Relapse
Sign in / Sign up

Export Citation Format

Share Document